|
Virtual Meetings 2023
Meet The Professor: Optimizing the Management of Colorectal CancerFor an up-to-date schedule of upcoming sessions in this series, please click here. PARTICIPATING FACULTY
Christopher Lieu, MD Associate Professor of Medicine Associate Director for Clinical Research Co-Director, GI Medical Oncology University of Colorado Cancer Center Aurora, Colorado Michael J Overman, MD Professor of Gastrointestinal Medical Oncology Chair, Executive Committee of the Medical Staff Associate Vice President, Cancer Network Research The University of Texas MD Anderson Cancer Center Houston, Texas John Strickler, MD Associate Professor Duke University Durham, North Carolina SERIES MODERATOR Neil Love, MD Research To Practice These activities are supported by educational grants from Lilly, Natera Inc, Seagen Inc, and Taiho Oncology Inc. Agenda
MODULE 1: Current and Future Role of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) MODULE 2: Integration of Immune Checkpoint Inhibitors into the Management of mCRC MODULE 3: Selection and Sequencing of Therapy for Patients with Multiregimen-Relapsed mCRC MODULE 4: Other Considerations in the Management of CRC; Promising Investigational Strategies
Target Audience
CE Credit American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Lieu — Consulting Agreement: Amgen Inc. Dr Overman — Consulting Agreements: Bayer HealthCare Pharmaceuticals, Gritstone bio, GSK, Merck, Nouscom, Pfizer Inc, Phanes Therapeutics Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc, Tempus. Dr Strickler — Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, GSK, Lilly, Natera Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc, Viatris; Consulting Agreement: Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Leap Therapeutics Inc, Lilly, Nektar, Sanofi, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, BeiGene Ltd, Pionyr Immunotherapeutics; Nonrelevant Financial Relationship: AStar D3.SURVEY PARTICIPANTS — Stacey A Cohen, MD — Advisory Committee: Bayer HealthCare Pharmaceuticals, Eisai Inc, Pfizer Inc, Taiho Oncology Inc; Consulting Agreement: Delcath Systems Inc; Contracted Research: Faeth, Natera Inc, Pfizer Inc, Tempus. Arvind Dasari, MD, MS — Advisory Committee: Bayer HealthCare Pharmaceuticals; Contracted Research: Eisai Inc, Guardant Health. Dustin Deming, MD — Advisory Committee: Bayer HealthCare Pharmaceuticals, Foundation Medicine, Illumina, Lilly, Pfizer Inc, Seagen Inc; Contracted Research: Aadi Bioscience, Arcus Biosciences, Bristol-Myers Squibb Company, Cornerstone Pharmaceuticals Inc, Curegenix, Genentech, a member of the Roche Group, Guardant Health, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Natera Inc, Pfizer Inc, Promega Corporation, Revolution Medicines, Strata Oncology, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Seagen Inc. SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from Lilly, Natera Inc, Seagen Inc, and Taiho Oncology Inc. |